Determination of aspirin responsiveness by use of whole blood platelet aggregometry

Clinical Chemistry

Volumn 53, Issue 4, 2007, Pages 614-619

  Ivandic, Boris T ^a,c   Giannitsis, Evangelos ^a   Schlick, Philipp ^a   Staritz, Peter ^a   Katus, Hugo A ^a   Hohlfeld, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Innere Medizin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; LYSINE ACETYLSALICYLATE; TERBOGREL; THROMBOXANE B2; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; IMPEDANCE; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD DONORS; COLLAGEN; CORONARY ARTERIOSCLEROSIS; DRUG RESISTANCE; ELECTRIC IMPEDANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; REFERENCE VALUES; SEX FACTORS; THROMBOXANE B2; TICLOPIDINE;

EID: 34147211305     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.081059     Document Type: Article

References (28)

1. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
2. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance [Review]. Arterioscler Thromb Vasc Biol 2004;24:1980-7. [Epub 2004 Sep 23].
3. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts [Review]. Rev Cardiovasc Med 2004;5:156-63.
4. Hankey GJ, Eikelboom JW. Aspirin resistance [Review]. Lancet 2006;367:606-17.
5. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs [Review]. J Thromb Haemost 2003;1:1710-3.
6. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
7. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
8. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-5.
9. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112:759-70.
10. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
11. Alexander JH, Harrington RA, Turtle RH, Berdan LG, Lincoff AM, Deckers JW, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators, Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999;83:1147-51.
12. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 1980;3:1350-8.
13. Ivandic BT, Schlick P, Staritz P, Kurz K, Katus HA, Giannitsis E. Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor. Clin Chem 2006;52:383-8.
14. Schror K, Seidel H. Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn Schmiedebergs Arch Pharmacol 1988;337:177-82.
15. Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation [Review]. Curr Opin Hematology 2001;8:263.
16. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991;87:571-80.
17. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991;78:154-62.
18. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-5.
19. Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R, Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin Appl Thromb Hemost 2005; 11:25-35.
20. Johnson MF, Davis RB. Effects of blood dilution on electrical impedance aggregometry. Thromb Res 1986;42:855-7.
21. Muller MR, Salat A, Pulaki S, Stangl P, Ergun E, Schreiner W, et al. Influence of hematocrit and platelet count on impedance and reactivity of whole blood for electrical aggregometry. J Pharmacol Toxicol Methods 1995;34:17-22.
22. Muller MR, Schreiner W, Wohlfahrt A, Salat A, Wolner E. The influence of sample age on collagen-induced platelet aggregation in whole blood. Thromb Res 1990;60:477-87.
23. Riess H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol 1986;85:50-6.
24. Sweeney JD, Labuzetta JW, Fitzpatrick JE. The effect of the platelet count on the aggregation response and adenosine triphosphate release in an impedance lumi-aggregometer. Am J Clin Pathol 1988;89:655-9.
25. Sweeney JD, Hoernig LA, Michnik BS, Fitzpatrick JE. Whole blood aggregometry: influence of sample collection and delay in study performance on test results. J Clin Pathol 1989;92:676-9.
26. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304. Epub 2005 Mar 7.
27. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002;13:37-40.
28. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106:2723-9. [Epub 005 Jun 21].